JP2008546672A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546672A5
JP2008546672A5 JP2008516350A JP2008516350A JP2008546672A5 JP 2008546672 A5 JP2008546672 A5 JP 2008546672A5 JP 2008516350 A JP2008516350 A JP 2008516350A JP 2008516350 A JP2008516350 A JP 2008516350A JP 2008546672 A5 JP2008546672 A5 JP 2008546672A5
Authority
JP
Japan
Prior art keywords
ifn
pharmaceutical composition
sequence encoding
family cytokine
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008516350A
Other languages
English (en)
Japanese (ja)
Other versions
JP5154412B2 (ja
JP2008546672A (ja
Filing date
Publication date
Priority claimed from ES200501468A external-priority patent/ES2302402B1/es
Application filed filed Critical
Publication of JP2008546672A publication Critical patent/JP2008546672A/ja
Publication of JP2008546672A5 publication Critical patent/JP2008546672A5/ja
Application granted granted Critical
Publication of JP5154412B2 publication Critical patent/JP5154412B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008516350A 2005-06-16 2006-06-16 インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用 Expired - Fee Related JP5154412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200501468 2005-06-16
ES200501468A ES2302402B1 (es) 2005-06-16 2005-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
PCT/ES2006/000353 WO2006134195A2 (es) 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa

Publications (3)

Publication Number Publication Date
JP2008546672A JP2008546672A (ja) 2008-12-25
JP2008546672A5 true JP2008546672A5 (cg-RX-API-DMAC10.html) 2012-11-29
JP5154412B2 JP5154412B2 (ja) 2013-02-27

Family

ID=37532659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008516350A Expired - Fee Related JP5154412B2 (ja) 2005-06-16 2006-06-16 インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用

Country Status (11)

Country Link
US (2) US7829077B2 (cg-RX-API-DMAC10.html)
EP (1) EP1905447A4 (cg-RX-API-DMAC10.html)
JP (1) JP5154412B2 (cg-RX-API-DMAC10.html)
CN (1) CN101257918B (cg-RX-API-DMAC10.html)
AU (1) AU2006258966B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0611988A2 (cg-RX-API-DMAC10.html)
CA (1) CA2612282C (cg-RX-API-DMAC10.html)
ES (1) ES2302402B1 (cg-RX-API-DMAC10.html)
MX (1) MX2007016060A (cg-RX-API-DMAC10.html)
RU (1) RU2413529C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006134195A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA106591C2 (uk) * 2008-07-23 2014-09-25 Тамара Алєксандровна Віткалова Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1
JP2010059081A (ja) * 2008-09-02 2010-03-18 Okayama Univ オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
WO2011098644A2 (es) 2010-02-09 2011-08-18 Proyecto De Biomedicina Cima, S.L. Composiciones para el tratamiento de enfermedades infecciosas y tumorales
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110636854A (zh) 2017-03-31 2019-12-31 阿卡尼斯生物技术F&E有限责任两合公司 非黑素瘤皮肤癌(nmsc)的预防和治疗
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN113197910B (zh) * 2021-05-14 2022-09-23 苏州大学 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348191B1 (en) * 1986-07-08 2002-02-19 Genetics Institute, Inc. Production and use of IL-6
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US6284237B1 (en) * 1986-07-08 2001-09-04 Steven C. Clark Methods of treatment using IL-6
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
TW589189B (en) * 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
ES2200646B1 (es) * 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
RU2222345C2 (ru) * 2002-01-21 2004-01-27 Волчек Игорь Анатольевич Фармацевтическая композиция цитокинового и иммуномодулирующего действия
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system

Similar Documents

Publication Publication Date Title
Miller et al. Clinical use of interferon‐γ
Isorce et al. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies
JP2008513356A5 (cg-RX-API-DMAC10.html)
CA2573207A1 (en) Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)
US20110027224A1 (en) Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
CN1764475A (zh) 治疗病毒性疾病和肝纤维化的干扰素药物治疗
AU2002228886B2 (en) Interferons, uses and compositions related thereto
EP2535057A2 (en) Compositions for the treatment of infectious and tumoural diseases
McHutchison et al. Future trends in managing hepatitis C
Nishimura et al. Acute onset of nephrotic syndrome during interferon-α retreatment for chronic active hepatitis C
CA2627531A1 (en) Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer
Brown Jr et al. 41 Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial
Tan et al. Gene cloning, sequencing, expression and biological activity of giant panda (Ailuropoda melanoleuca) interferon-α
Clark et al. Novel interferons for treatment of hepatitis C virus
CN1798572A (zh) 用于严重急性呼吸道综合征(SARS)的干扰素β
Witthoeft et al. [655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS SUPERIOR COMPARED TO HIGH DOSE CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C
JPWO2004083186A1 (ja) ウイルス性肝炎治療剤及び制癌剤
Dev et al. Current standard of care in hepatitis C virus infection
Blum LOCALLY PRODUCED PEG INTERFERON AS AN OPPORTUNITY TO TREAT HCV IN LOW AND MID-INCOME COUNTRIES
RU2401268C2 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (R)-6-ЦИКЛОПЕНТИЛ-6-(2-(2,6-ДИЭТИЛПИРИДИН-4-ИЛ)ЭТИЛ)-3-((5,7-ДИМЕТИЛ-[1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-2-ИЛ)МЕТИЛ)-4-ГИДРОКСИ-5,6-ДИГИДРОПИРАН-2-ОНА, ЕЕ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
Piguet et al. 42 The mitochondrial AMP-lysine hydrolase, HINT2, sensitizes experimental hepatocellular carcinoma to FAS-induced apoptosis
Yamamoto et al. Creation of Interferon-a8 Mutants with Amino Acid Substitutions Against Interferon-[alpha] Receptor-2 Binding Sites Using Phage Display System and Evaluation of Their Biologic Properties
Tacke LETTER TO
Zehnter et al. [656] THE ROLE OF GLOMERULAR FILTRATION RATE (GFR) FOR TREATMENT WITH PEGINTERFERON ALFA 2a (PEG) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)
Müller of Type I Interferons